Showing results (61-70 of 119) with videos related to

Sort By:
Pageof 12
Journal of Clinical Microbiology|November 1, 1996
Evaluation of Chiron HIV-1/HIV-2 recombinant immunoblot assayR L Kline, D McNairn, M Holodniy, et al.
Annals of the Rheumatic Diseases|January 29, 2005
Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trialC Antoni, G G Krueger, K de Vlam, et al.
Journal of the American Academy of Dermatology|December 1, 1991
Evaluation of halobetasol propionate ointment in the treatment of plaque psoriasis: report on two double-blind, vehicle-controlled studiesJ Bernhard, C Whitmore, C Guzzo, et al.
Bone Marrow Transplantation|December 23, 2003
Evaluation of histogenesis of B-lymphocytes in pediatric EBV-related post-transplant lymphoproliferative disordersN Abed, J T Casper, B M Camitta, et al.
Environmental Research|November 14, 1997
Air pollution and doctors' house calls: results from the ERPURS system for monitoring the effects of air pollution on public health in Greater Paris, France, 1991-1995. Evaluation des Risques de la Pollution Urbaine pour la SantéS Medina, A Le Tertre, P Quénel, et al.
The British Journal of Dermatology|July 17, 2008
Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasisS R Feldman, A B Gottlieb, M Bala, et al.
Bone Marrow Transplantation|October 31, 2002
Cognitive and psychosocial functioning of pediatric hematopoietic stem cell transplant patients: a prospective longitudinal studyM J Kupst, B Penati, B Debban, et al.
American Journal of Public Health|February 26, 2015
Drug Use, Sexual Risk, and Syndemic Production Among Men Who Have Sex With Men Who Engage in Group Sexual EncountersSabina Hirshfield, Eric W Schrimshaw, Ronald D Stall, et al.
Journal of Clinical Pharmacology|September 1, 1995
Efficacy and pharmacokinetics of two formulations of cyclosporine A in patients with psoriasisC A Elder, M Moore, C T Chang, et al.
The British Journal of Dermatology|February 24, 2012
Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 yearsA B Kimball, K B Gordon, S Fakharzadeh, et al.
Pageof 12